Last reviewed · How we verify
NCT04878965: Smartwatch
Smartwatches to Manage Stress and Anxiety in Residential Settings
NA trial testing Smartwatch in Baseline in 17 participants. Completed in 28 February 2024.
28 February 2024
Quick facts
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 17 |
| Start date | 26 April 2021 |
| Primary completion | 28 February 2024 |
| Estimated completion | 28 February 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Smartwatch
Conditions studied
- Baseline — all drugs for Baseline →
- Technology — all drugs for Technology →
Sponsor
Centre for Addiction and Mental Health — full company profile →
Who can join
18 and older, any sex, with Baseline or Technology. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to conduct a prospective evaluation of a smartwatch technology and an associated application (developed by Awake Labs) in a clinical cohort from Centre for Addiction and Mental Health (CAMH) Adult Neurodevelopmental Services (ANS) and adults with developmental disabilities in the community who have received a watch.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04878965
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Smartwatch
Trials testing the same drug.
- NCT06011395 — Smart Wearable Insights to Prevent Exacerbations and Recurrence - Rehabilitation Study: SWIPER-REHAB · not yet recruiting
- NCT06011356 — Smart Watch Insights for Prevention of Exacerbations and Enhance Rehabilitation - Movement Study · active not recruiting
- NCT05771142 — Evaluation of an Innovative Smart T-shirt Capable to Monitor ECG Signal and Related Parameters Through the Comparison Wi · unknown
- NCT05463250 — Smartwatch and Physician Well-Being · NA · completed
- NCT05431348 — Effect of stRess and exeRcize on the Outcome After Chemo-Radiation · completed
Other Centre for Addiction and Mental Health trials
Trials by the same sponsor.
- NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
- NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
- NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
- NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04878965 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
- Last refreshed: 30 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04878965.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing